martedì, 24 novembre 2020
Medinews
19 Marzo 2018

NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC

March 16, 2018 – The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC (mCRC). The new dosing scheme calls for a starting dose of 80 mg/daily on days 1 to 7, escalating to 120 mg/daily on days 8 to 14, and concluding with 160 mg/daily on days 15 to 21. For subsequent cycles, the NCCN recommends 160 … (leggi tutto)

TORNA INDIETRO